Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA projectMarina Elena Cazzaniga, A. V. Snegovoy, Romano Danesi et al.|Frontiers in Oncology|2023Cited by 10